MedTrace Logo

Effect of Alpha-lipoic Acid on Biochemical Markers and Important Outcomes in Patients Admitted to Intensive Care Units

NCT01888861 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-06-28

No results posted yet for this study

Summary

Increasing Reactive oxygen and nitrogen production occurred simultaneously with decreasing serum and intracellular level of antioxidants and enzymes in critical ill patients, which result in increasing ventilator dependency and length of stay in intensive care unit and it also accelerate organ failures in patients. In this double blind clinical trial, the investigators examine effect of alfa-lipoic acid on those patients who admitted to intensive care unit that the investigators expect to stay for more than 7 days in this ward and who have tube feeding and don't have severe liver and kidney failure, AIDS and hepatitis. After randomization of included patients by block randomization the investigators will give 900mg/day alfa-lipoic acid for ten days to treatment group and identical placebo to control group by naso-gastric tube. The purposes of this study are decreasing ventilator dependency period, length of stay in ICU, mortality and decelerate of organ failures.

Conditions

Interventions

DIETARY_SUPPLEMENT

alpha-lipoic acid

the patients in this arm receive 900mg alpha-lipoic acid through NG tube.

DRUG

placebo

the patients in this arm were received 900mg placebo through NG tube.

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    collaborator OTHER

  • najmeh hejazi

    lead OTHER

Principal Investigators

  • Najmeh Hejazi, Ph.D · Shiraz University of Medical Sciences,Nutrition department

  • Zohreh Mazloom, PhD · Shiraz University of Medical Sciences, Faculty of Nutrition

  • Farid Zand, MD · Shiraz University of Medical Sciences, anesthesiology and critical care research center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888861 on ClinicalTrials.gov